logo

FDA Calendar

Share
Company Name TG Therapeutics Inc.
Drug Name Umbralisib (NDA)
Event Name FDA decision on Umbralisib as a treatment for for patients with previously treated marginal zone lymphoma
Event Date 02/15/2021
Outcome Date
Outcome
Drug Status Priority Review
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar